Our work in pharmacology and drug discovery has a sustained impact on the understanding and treatment of major global health burdens.
Our major research capability strengths are pharmacology, structural biology, target identification and translational biology.
Our principal therapeutic focus areas are neurological disease, cardiovascular disease and metabolic disease. We have interests in pain, inflammatory disease and cancer. We also serve as the headquarters of the ARC Training Centre for Cryo-Electron Microscopy of Membrane Proteins for Drug Discovery.
We have specific interests in:
- the structure and function of G protein-coupled receptors (GPCRs),
- the role of allostery and bias in receptor signalling, particularly in neuroscience,
- the genes, proteins and pathways that are important in metabolic disease, and
- the development of new treatments for heart failure resulting from interruptions in coronary blood supply (such as in heart attack) or as a result of diabetes.